Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)

NCT06915233 is registered in ClinicalTrials.gov with Vericel Corporation as lead sponsor.

NCT NCT06915233
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06915233 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)
Lead sponsor
Vericel Corporation
Phase
Phase 3
Overall status
Recruiting
Start date
May 28, 2026
Completion date
July 31, 2030
Enrollment
309 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

articular cartilage defect, chondral defect